Cidara Therapeutics, Inc.
DelistedCIK 1610618fmd_1GN9KX1QZV8G1KJ10M9RDWCRKMManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2013 to Sep 30, 2025, 48 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | 64 | 23 | 1 |
| Research and development | 23 | 36 | 43 | 49 | 46 | 68 | 73 | 77 | 37 | 72 |
| Selling, general and administrative | – | – | – | – | – | – | – | 21 | 18 | – |
| Total operating expenses | 32 | 48 | 56 | 63 | 63 | 84 | 92 | 98 | 50 | 177 |
| Operating income | (32) | (48) | (56) | (63) | (42) | (72) | (42) | (34) | (27) | (176) |
| Interest expense | – | – | – | – | 0 | 0 | 0 | 0 | – | – |
| Other non-operating income (expense) | 0 | 0 | (0) | 4 | 1 | (0) | (0) | 0 | 2 | 6 |
| Income before taxes | – | – | – | – | – | (72) | (42) | (33) | (25) | (170) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | (72) | (42) | (34) | (25) | (170) |
| Net income | (32) | (48) | (56) | (59) | (41) | (72) | (42) | (34) | (23) | (170) |
| Net income to common shareholders | – | (48) | (56) | (69) | (41) | (75) | (42) | (30) | – | – |